Skip to main content

Table 2 In vivo studies performed with the proprietary yeast β-glucan preparation Yestimun ®

From: Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan

Title/reference Study design/duration/dosage Main results
Increased interleukin-10 but unchanged insulin sensitivity after 4 weeks of (1, 3)(1, 6)-beta-glucan consumption in overweight humans [40] Randomized, double-blind, placebo-controlled, crossover study; In overweight or obese subject the orally applied β-glucan leads to the following results:
12 healthy overweight and obese subjects 3 × 0.5 g of (1,3)(1,6)-D-glucan (Biolex-Beta HP*) or placebo per day 2 × 4 weeks • significant increase of both circulating levels and adipose tissue messenger RNA (mRNA) expression of the anti-inflammatory cytokine IL-10
• insulin sensitivity was unaffected
• no increase in non specific proinflammatory markers CRP, IL-6 and MCP-1/CCL-2
• circulating levels and mRNA expression of proinflammatory cytokines were unaffected
A double-blind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system [39] Randomized, double-blind, placebo-controlled clinical trial; Supplementation with 1,3/1,6-D-glucan led compared to placebo to:
100 healthy adults with recurring common colds received 1,3/1,6-D-glucan (Yestimun®) 900 mg/day or a placebo for 26 weeks • significant more subjects without incidences of common cold
• significant less infections during the most intense infection season
• significant reduction of the typical cold symptoms: “sore throat and/or difficulty swallowing”, “hoarseness and/or cough” and “runny nose”
Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body’s defense against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects [38] Randomized, double-blind, placebo-controlled clinical trial; Supplementation with 1,3/1,6-D-glucan led compared to placebo to:
162 healthy adults with recurring common colds received 1,3/1,6-D-glucan (Yestimun®) 900 mg/day or a placebo for 16 weeks • a significant reduced number (by 25%) of common cold infections in the per protocol population
• a 15% lowered mean symptom score
   • significant reduced sleep difficulties usually caused by common cold episodes
  1. *Yestimun® was previously called Biolex-Beta HP.